INDP — Indaptus Therapeutics Share News
0.000.00%
Last trade - 00:00- $459.21m
- $447.65m
Indaptus Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
Brief: Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering And Concurrent Private Placement
Brief: Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors
Indaptus Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
Indaptus Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Indaptus Therapeutics Sees Common Stock Offering Of Up To $5.2 Million - SEC Filing
Brief: Indaptus Therapeutics FY EPS USD -1.83
Brief: Indaptus Therapeutics Announces Positive Results From Second Cohort Of Phase 1 Trial
Indaptus Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
Brief: Indaptus Therapeutics Says Decoy20 Demonstrated a Broad Immune Response of More than 50 Cytokines and Chemokines in Patients Following a Single Dose
Brief: Indaptus Therapeutics Q2 EPS USD -0.39
Indaptus Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman Chief Medical Officer
Indaptus Therapeutics Inc expected to post a loss of 58 cents a share - Earnings Preview
Brief: Indaptus Therapeutics Reports Q1 2023 Financial Results And Provides Corporate Update
Brief: Indaptus Therapeutics' Chief Scientific Officer Michael Newman Named A Chair Of 4th Sting & Tlr-Targeting Therapies Summit
Indaptus rises on positive pre-clinical efficacy data for anti-tumor platform
Brief: Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy Of Decoy, Its Bacteria-Based Immunotherapy Platform Technology, At The American Association For Cancer Research Conference 2023
Brief: Indaptus Therapeutics Receives Brazilian Patent Allowance For Decoy Platform